Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1981 1
2015 1
2016 2
2017 1
2018 1
2019 1
2020 6
2021 12
2022 17
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
Ferrannini G, Savarese G, Cosentino F. Ferrannini G, et al. Heart Fail Clin. 2022 Oct;18(4):551-559. doi: 10.1016/j.hfc.2022.03.009. Heart Fail Clin. 2022. PMID: 36216485 Free article. Review.
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI).
Lundin M, Ferrannini G, Mellbin L, Johansson I, Norhammar A, Näsman P, Shahim B, Smetana S, Venkateshvaran A, Wang A, Sörensson P, Rydén L. Lundin M, et al. Among authors: ferrannini g. Diabetes Res Clin Pract. 2022 Nov;193:110141. doi: 10.1016/j.diabres.2022.110141. Epub 2022 Nov 4. Diabetes Res Clin Pract. 2022. PMID: 36336088 Free article. Clinical Trial.
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial.
Fortin E, Lundin M, Mellbin L, Norhammar A, Näsman P, Smetana S, Sörensson P, Ferrannini E, Rydén L, Ferrannini G. Fortin E, et al. Among authors: ferrannini g. Cardiovasc Diabetol. 2023 Aug 11;22(1):208. doi: 10.1186/s12933-023-01950-0. Cardiovasc Diabetol. 2023. PMID: 37568149 Free PMC article. Clinical Trial.
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry.
Nguyen NV, Lindberg F, Benson L, Ferrannini G, Imbalzano E, Mol PGM, Dahlström U, Rosano GMC, Ezekowitz J, Butler J, Lund LH, Savarese G. Nguyen NV, et al. Among authors: ferrannini g. Eur J Heart Fail. 2023 Aug;25(8):1418-1428. doi: 10.1002/ejhf.2939. Epub 2023 Jun 29. Eur J Heart Fail. 2023. PMID: 37323078 Free article.
Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlström U, Sinagra G, Rosano GMC, Savarese G. Stolfo D, et al. Among authors: ferrannini g. Eur J Heart Fail. 2023 Sep;25(9):1648-1658. doi: 10.1002/ejhf.2971. Epub 2023 Jul 24. Eur J Heart Fail. 2023. PMID: 37419495 Free article.
50 results